Suchergebnisse - "Yang, Eddy S"

PubPharm (7)

1

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

enthalten in: Breast cancer research and treatment | 2023

von Vaklavas, C. | Stringer-Reasor, E. | Elkhanany, A. | +8

2

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations : Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B

enthalten in: JCO precision oncology | 2022

von Bedard, P. | Li, S. | Wisinski, K. | +18

3

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition

enthalten in: Molecular cancer therapeutics | 2018

von Wielgos, M. | Zhang, Z. | Rajbhandari, R. | +9

4

Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors

enthalten in: Molecular cancer research : MCR | 2017

von Wielgos, M. | Rajbhandari, R. | Cooper, T. | +3

5

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers

enthalten in: Breast cancer research and treatment | 2015

von Stanley, J. | Klepczyk, L. | Keene, K. | +8

6

HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair

enthalten in: Cancer research | 2012

von Nowsheen, S. | Cooper, T. | Bonner, J. | +2

7

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells

enthalten in: PloS one | 2012

von Nowsheen, S. | Cooper, T. | Stanley, J. | +1

1
[1]